Fallon B A, Liebowitz M R, Campeas R, Schneier F R, Marshall R, Davies S, Goetz D, Klein D F
Department of Psychiatry, Columbia University, New York State Psychiatric Institute, New York 10032, USA.
Arch Gen Psychiatry. 1998 Oct;55(10):918-24. doi: 10.1001/archpsyc.55.10.918.
Uncontrolled reports suggest that intravenous clomipramine hydrochloride may be effective for patients with obsessive-compulsive disorder (OCD) who are nonresponsive to oral clomipramine.
Fifty-four patients with oral clomipramine-refractory OCD were randomized to receive 14 infusions of either placebo or clomipramine hydrochloride, starting at 25 mg/d and increasing to 250 mg/d. Ratings were conducted double-blind after infusion 14 among 54 patients, single-blind 1 week later among 39 patients, and nonblind 1 month later among 31 patients. Response was based on a Clinical Global Impressions rating of at least "much improved."
Six (21%) of 29 patients randomized to receive intravenous (i.v.) clomipramine vs 0 of 25 patients given i.v. placebo were responders after 14 infusions (df = 1, P<.02). Dimensional ratings after infusion 14 revealed significant (P = .007) improvement on the National Institute of Mental Health-Obsessive-Compulsive Scale and the Clinical Global Impressions Scale (P = .03), but not the Yale-Brown Obsessive Compulsive Scale. One week later, all dimensional measures of OCD showed significant improvement. At 1 week post-i.v., 9 (43%) of 21 patients initially randomized to i.v. clomipramine and treated subsequently with oral clomipramine were responders, whereas 0 of 18 patients initially randomized to receive i.v. placebo and treated subsequently with several days of open-label i.v. clomipramine responded (df = 1, P<.002). Of the 31 patients assessed 1 month after i.v. infusion (treatment not controlled), 18 (58.1%) were responders. Intravenous clomipramine treatment was safe with no serious adverse consequences.
Intravenous clomipramine is more effective than i.v. placebo for patients with OCD with a history of inadequate response or intolerance to oral clomipramine. Further study of this promising treatment for refractory OCD is needed.
非对照研究报告表明,对于对口服氯米帕明无反应的强迫症(OCD)患者,静脉注射盐酸氯米帕明可能有效。
54例对口服氯米帕明难治的强迫症患者被随机分为两组,分别接受14次安慰剂或盐酸氯米帕明静脉输注,起始剂量为25mg/d,逐渐增加至250mg/d。在54例患者输注14次后进行双盲评定,1周后在39例患者中进行单盲评定,1个月后在31例患者中进行非盲评定。疗效判定基于临床总体印象评定至少为“明显改善”。
随机接受静脉注射氯米帕明的29例患者中有6例(21%)在输注14次后有反应,而接受静脉注射安慰剂的25例患者中无1例有反应(自由度 = 1,P<0.02)。输注14次后的维度评定显示,在国立精神卫生研究所强迫症量表和临床总体印象量表上有显著改善(P = 0.007),但在耶鲁-布朗强迫症量表上无改善。1周后,强迫症的所有维度指标均显示有显著改善。静脉注射后1周,最初随机接受静脉注射氯米帕明并随后接受口服氯米帕明治疗的21例患者中有9例(43%)有反应,而最初随机接受静脉注射安慰剂并随后接受数天开放标签静脉注射氯米帕明治疗的18例患者中无1例有反应(自由度 = 1,P<0.002)。在静脉输注1个月后评估的31例患者中(治疗未设对照),18例(58.1%)有反应。静脉注射氯米帕明治疗安全,无严重不良后果。
对于有口服氯米帕明反应不佳或不耐受史的强迫症患者,静脉注射氯米帕明比静脉注射安慰剂更有效。需要对这种有前景的难治性强迫症治疗方法进行进一步研究。